ArticleNPJ precision oncology2026
OncoGen.AI: an integrated platform for automated genomic analysis and reporting in precision oncology.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The translation of complex cancer genomics into clinically actionable insights is a critical bottleneck in precision oncology. To automate the entire workflow, we present OncoGen.AI, an end-to-end, containerized platform that automates the process from raw sequencing data to a final clinical report. The platform integrates platform-agnostic pipelines (Illumina/Ion Torrent) for variant calling, copy number variation (CNV), and tumor mutational burden (TMB) analysis. Its core innovation is a clinically relevant Knowledge Graph comprising 20,242,772 triples across 11 node types, integrating data from domain-specific databases such as COSMIC, ClinVar, and others for evidence-based interpretation. The workflow culminates in a structured clinical report automatically generated by Google Gemini on the curated evidence extracted by the Knowledge Graph. When benchmarked against a diverse cohort of 13 clinical tumor exomes and validated across seven publicly available datasets, OncoGen.AI recovered 100% of pathogenic mutations identified by proprietary software (DRAGEN and Torrent Suite). Furthermore, in comparative analyses against other leading tools, OncoGen.AI demonstrated superior sensitivity, uniquely identifying clinically significant mutations in challenging Ion Torrent datasets that were otherwise missed. By providing a transparent "glass box" solution that bridges the gap between raw data and clinical action, OncoGen.AI is a comprehensive tool poised to accelerate reproducible decision-making in precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.